<DOC>
	<DOCNO>NCT00727506</DOCNO>
	<brief_summary>Phase I Part : To determine maximum tolerate dose ( MTD ) pharmacokinetics BIBW 2992 administered combination TMZ patient recurrent malignant glioma ( WHO Grade III IV ) . Phase II Part : To estimate efficacy safety BIBW 2992 monotherapy BIBW 2992 / TMZ combination therapy compare TMZ monotherapy ( three treatment arm ) patient recurrent GBM . To evaluate molecular determinant response BIBW 2992 .</brief_summary>
	<brief_title>BIBW 2992 ( Afatinib ) With Without Daily Temozolomide Treatment Patients With Recurrent Malignant Glioma</brief_title>
	<detailed_description />
	<mesh_term>Glioma</mesh_term>
	<criteria>Inclusion criterion : Phase I Part : 1 . Histologicallyconfirmed WHO Grade III IV malignant glioma recurrent prior chemoradiotherapy . Patients prior lowgrade glioma eligible histologic assessment demonstrate transformation WHO Grade III IV malignant glioma . 2 . Age least 18 year entry 3 . KPS least 60 % 4 . Patients must recover previous surgery chemotherapy . 5 . Written inform consent consistent local law ICHGCP guideline . Phase II Part : 1 . Histologicallyconfirmed WHO Grade IV malignant glioma first episode recurrence prior combine chemoradiotherapy . Patients prior lowgrade glioma eligible histologic assessment demonstrate transformation WHO Grade IV malignant glioma prior treatment include temozolomide chemotherapy radiotherapy . 2 . Bidimensionally measurable disease minimum measurement 1 cm ( 10 mm ) one diameter Gd MRI perform within 14 day prior first treatment ( Day 1 ) . 3 . Age least 18 year entry 4 . KPS least 70 % 5 . Patients must recover previous surgery chemotherapy . 6 . Written inform consent consistent local law ICHGCP guideline . 7 . Patients receive corticosteroid receive stable decrease dose least 14 day start study treatment . Exclusion criterion : Phase I Phase II Parts : 1 . Less 12 week radiotherapy start study treatment , unless new enhance lesion outside radiation field radiologically progressive two consecutive MRI scan least four week apart biopsyproven recurrence . 2 . Less two week surgical resection ( one week prior stereotactic biopsy ) major surgical procedure . 3 . Less two week previous chemotherapy ( 6 week nitrosureas ) . 4 . Treatment investigational drug ; participation another clinical study within past 2 week start therapy concomitantly study . 5 . Progressive disease toxicity =CTCAEv3 Grade 3 protract temozolomide dosing ( define temozolomide administer 5 days/28 day cycle ) . 6 . Active infectious disease require intravenous therapy . 7 . Known human immunodeficiency virus ( HIV ) infection chronic Hepatitis B C. 8 . Gastrointestinal disorder may interfere absorption study drug chronic diarrhea . 9 . Serious illness concomitant nononcological disease consider investigator incompatible protocol . 10 . Patient &lt; 3 year free another primary malignancy except : primary malignancy either currently clinically significant require active intervention ( basal cell skin cancer cervical carcinoma situ ) 11 . Cardiac leave ventricular function rest ejection fraction &lt; 50 % . 12 . Absolute neutrophil count ( ANC ) less 1500/mm3 . 13 . Platelet count less 100,000/mm3 . 14 . Bilirubin great 1.5 x upper limit institutional norm . 15 . Aspartate amino transferase ( AST ) great 3 x upper limit institutional norm . 16 . Serum creatinine great 1.5 x upper limit institutional norm . 17 . Patients sexually active unwilling use medically acceptable method contraception . 18 . Pregnancy breastfeed . 19 . Patients unable comply protocol . 20 . Known preexist interstitial lung disease ( ILD ) . Phase I part : 1 . Less four week prior treatment bevacizumab . Phase II Part : 1 . Prior EGFRdirected therapy . 2 . Prior bevacizumab therapy . 3 . Patients present second high number episode recurrence . 4 . Requirement treatment prohibit concomitant medication list Section 4.2.2 ( Restrictions regard concomitant treatment ) .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2016</verification_date>
</DOC>